Skip to Main Content

Tarsheen Sethi, MD, MSCI

Assistant Professor of Medicine (Hematology)

Contact Information

Tarsheen Sethi, MD, MSCI

Research Summary

Her research is aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies focusing on lymphoma.

Extensive Research Description

Her research is aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies focusing on lymphoma.

Coauthors

Research Interests

Hodgkin Disease; Lymphoma

Selected Publications

Clinical Trials

ConditionsStudy Title
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Non-Hodgkin's LymphomaA Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Non-Hodgkin's LymphomaA Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Phase IA Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Hodgkin's LymphomaA Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaA Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Lymphoid Leukemia; Non-Hodgkin's Lymphoma; Phase IAn Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia